PMC:7228307 / 47031-47486 JSONTXT

{"project":"LitCovid_Glycan-Motif-Structure","denotations":[{"id":"T4","span":{"begin":265,"end":271},"obj":"https://glytoucan.org/Structures/Glycans/G82576YO"}],"text":"There are six afucosylated antibodies in late‐stage clinical trials or approved for treatment (Table 4). Notable is obinutuzumab, an afucosyl anti‐CD20 mAb which nearly doubles progression‐free survival in chronic lymphocytic leukemia patients as compared with the fucose‐containing rituximab.68 This dramatic improvement in clinical utility reinforces the value of glycan engineering specifically and of Fc engineering generally in anticancer treatments."}

{"project":"LitCovid-PubTator","denotations":[{"id":"900","span":{"begin":235,"end":243},"obj":"Species"},{"id":"901","span":{"begin":116,"end":128},"obj":"Chemical"},{"id":"902","span":{"begin":265,"end":271},"obj":"Chemical"},{"id":"903","span":{"begin":283,"end":292},"obj":"Chemical"},{"id":"904","span":{"begin":366,"end":372},"obj":"Chemical"},{"id":"905","span":{"begin":206,"end":234},"obj":"Disease"}],"attributes":[{"id":"A900","pred":"tao:has_database_id","subj":"900","obj":"Tax:9606"},{"id":"A901","pred":"tao:has_database_id","subj":"901","obj":"MESH:C543332"},{"id":"A902","pred":"tao:has_database_id","subj":"902","obj":"MESH:D005643"},{"id":"A903","pred":"tao:has_database_id","subj":"903","obj":"MESH:D000069283"},{"id":"A904","pred":"tao:has_database_id","subj":"904","obj":"MESH:D011134"},{"id":"A905","pred":"tao:has_database_id","subj":"905","obj":"MESH:D015451"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"There are six afucosylated antibodies in late‐stage clinical trials or approved for treatment (Table 4). Notable is obinutuzumab, an afucosyl anti‐CD20 mAb which nearly doubles progression‐free survival in chronic lymphocytic leukemia patients as compared with the fucose‐containing rituximab.68 This dramatic improvement in clinical utility reinforces the value of glycan engineering specifically and of Fc engineering generally in anticancer treatments."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T383","span":{"begin":214,"end":225},"obj":"Body_part"},{"id":"T384","span":{"begin":265,"end":271},"obj":"Body_part"}],"attributes":[{"id":"A383","pred":"fma_id","subj":"T383","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A384","pred":"fma_id","subj":"T384","obj":"http://purl.org/sig/ont/fma/fma82790"}],"text":"There are six afucosylated antibodies in late‐stage clinical trials or approved for treatment (Table 4). Notable is obinutuzumab, an afucosyl anti‐CD20 mAb which nearly doubles progression‐free survival in chronic lymphocytic leukemia patients as compared with the fucose‐containing rituximab.68 This dramatic improvement in clinical utility reinforces the value of glycan engineering specifically and of Fc engineering generally in anticancer treatments."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T81","span":{"begin":206,"end":234},"obj":"Disease"},{"id":"T82","span":{"begin":214,"end":234},"obj":"Disease"},{"id":"T83","span":{"begin":226,"end":234},"obj":"Disease"}],"attributes":[{"id":"A81","pred":"mondo_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/MONDO_0004948"},{"id":"A82","pred":"mondo_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/MONDO_0005402"},{"id":"A83","pred":"mondo_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/MONDO_0005059"}],"text":"There are six afucosylated antibodies in late‐stage clinical trials or approved for treatment (Table 4). Notable is obinutuzumab, an afucosyl anti‐CD20 mAb which nearly doubles progression‐free survival in chronic lymphocytic leukemia patients as compared with the fucose‐containing rituximab.68 This dramatic improvement in clinical utility reinforces the value of glycan engineering specifically and of Fc engineering generally in anticancer treatments."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T815","span":{"begin":405,"end":407},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"There are six afucosylated antibodies in late‐stage clinical trials or approved for treatment (Table 4). Notable is obinutuzumab, an afucosyl anti‐CD20 mAb which nearly doubles progression‐free survival in chronic lymphocytic leukemia patients as compared with the fucose‐containing rituximab.68 This dramatic improvement in clinical utility reinforces the value of glycan engineering specifically and of Fc engineering generally in anticancer treatments."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T238","span":{"begin":265,"end":271},"obj":"Chemical"},{"id":"T239","span":{"begin":283,"end":292},"obj":"Chemical"}],"attributes":[{"id":"A238","pred":"chebi_id","subj":"T238","obj":"http://purl.obolibrary.org/obo/CHEBI_33984"},{"id":"A239","pred":"chebi_id","subj":"T239","obj":"http://purl.obolibrary.org/obo/CHEBI_64357"}],"text":"There are six afucosylated antibodies in late‐stage clinical trials or approved for treatment (Table 4). Notable is obinutuzumab, an afucosyl anti‐CD20 mAb which nearly doubles progression‐free survival in chronic lymphocytic leukemia patients as compared with the fucose‐containing rituximab.68 This dramatic improvement in clinical utility reinforces the value of glycan engineering specifically and of Fc engineering generally in anticancer treatments."}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T50","span":{"begin":265,"end":271},"obj":"Chemical"}],"attributes":[{"id":"A50","pred":"chebi_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/CHEBI_33984"}],"text":"There are six afucosylated antibodies in late‐stage clinical trials or approved for treatment (Table 4). Notable is obinutuzumab, an afucosyl anti‐CD20 mAb which nearly doubles progression‐free survival in chronic lymphocytic leukemia patients as compared with the fucose‐containing rituximab.68 This dramatic improvement in clinical utility reinforces the value of glycan engineering specifically and of Fc engineering generally in anticancer treatments."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"900","span":{"begin":235,"end":243},"obj":"Species"},{"id":"901","span":{"begin":116,"end":128},"obj":"Chemical"},{"id":"902","span":{"begin":265,"end":271},"obj":"Chemical"},{"id":"903","span":{"begin":283,"end":292},"obj":"Chemical"},{"id":"904","span":{"begin":366,"end":372},"obj":"Chemical"},{"id":"905","span":{"begin":206,"end":234},"obj":"Disease"}],"attributes":[{"id":"A904","pred":"pubann:denotes","subj":"904","obj":"MESH:D011134"},{"id":"A902","pred":"pubann:denotes","subj":"902","obj":"MESH:D005643"},{"id":"A901","pred":"pubann:denotes","subj":"901","obj":"MESH:C543332"},{"id":"A900","pred":"pubann:denotes","subj":"900","obj":"Tax:9606"},{"id":"A903","pred":"pubann:denotes","subj":"903","obj":"MESH:D000069283"},{"id":"A905","pred":"pubann:denotes","subj":"905","obj":"MESH:D015451"}],"text":"There are six afucosylated antibodies in late‐stage clinical trials or approved for treatment (Table 4). Notable is obinutuzumab, an afucosyl anti‐CD20 mAb which nearly doubles progression‐free survival in chronic lymphocytic leukemia patients as compared with the fucose‐containing rituximab.68 This dramatic improvement in clinical utility reinforces the value of glycan engineering specifically and of Fc engineering generally in anticancer treatments."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T272","span":{"begin":0,"end":104},"obj":"Sentence"},{"id":"T273","span":{"begin":105,"end":455},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"There are six afucosylated antibodies in late‐stage clinical trials or approved for treatment (Table 4). Notable is obinutuzumab, an afucosyl anti‐CD20 mAb which nearly doubles progression‐free survival in chronic lymphocytic leukemia patients as compared with the fucose‐containing rituximab.68 This dramatic improvement in clinical utility reinforces the value of glycan engineering specifically and of Fc engineering generally in anticancer treatments."}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T589","span":{"begin":147,"end":151},"obj":"Protein"}],"attributes":[{"id":"A589","pred":"uniprot_id","subj":"T589","obj":"https://www.uniprot.org/uniprot/Q3C2E2"},{"id":"A590","pred":"uniprot_id","subj":"T589","obj":"https://www.uniprot.org/uniprot/Q13963"},{"id":"A591","pred":"uniprot_id","subj":"T589","obj":"https://www.uniprot.org/uniprot/P19437"},{"id":"A592","pred":"uniprot_id","subj":"T589","obj":"https://www.uniprot.org/uniprot/P11836"},{"id":"A593","pred":"uniprot_id","subj":"T589","obj":"https://www.uniprot.org/uniprot/P08984"},{"id":"A594","pred":"uniprot_id","subj":"T589","obj":"https://www.uniprot.org/uniprot/B4DT24"},{"id":"A595","pred":"uniprot_id","subj":"T589","obj":"https://www.uniprot.org/uniprot/A6NMS4"}],"text":"There are six afucosylated antibodies in late‐stage clinical trials or approved for treatment (Table 4). Notable is obinutuzumab, an afucosyl anti‐CD20 mAb which nearly doubles progression‐free survival in chronic lymphocytic leukemia patients as compared with the fucose‐containing rituximab.68 This dramatic improvement in clinical utility reinforces the value of glycan engineering specifically and of Fc engineering generally in anticancer treatments."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T382","span":{"begin":214,"end":225},"obj":"Body_part"},{"id":"T383","span":{"begin":265,"end":271},"obj":"Body_part"}],"attributes":[{"id":"A383","pred":"fma_id","subj":"T383","obj":"http://purl.org/sig/ont/fma/fma82790"},{"id":"A382","pred":"fma_id","subj":"T382","obj":"http://purl.org/sig/ont/fma/fma62863"}],"text":"There are six afucosylated antibodies in late‐stage clinical trials or approved for treatment (Table 4). Notable is obinutuzumab, an afucosyl anti‐CD20 mAb which nearly doubles progression‐free survival in chronic lymphocytic leukemia patients as compared with the fucose‐containing rituximab.68 This dramatic improvement in clinical utility reinforces the value of glycan engineering specifically and of Fc engineering generally in anticancer treatments."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T36","span":{"begin":206,"end":234},"obj":"Disease"}],"attributes":[{"id":"A36","pred":"mondo_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/MONDO_0004948"}],"text":"There are six afucosylated antibodies in late‐stage clinical trials or approved for treatment (Table 4). Notable is obinutuzumab, an afucosyl anti‐CD20 mAb which nearly doubles progression‐free survival in chronic lymphocytic leukemia patients as compared with the fucose‐containing rituximab.68 This dramatic improvement in clinical utility reinforces the value of glycan engineering specifically and of Fc engineering generally in anticancer treatments."}

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T32","span":{"begin":206,"end":234},"obj":"Phenotype"}],"attributes":[{"id":"A32","pred":"hp_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/HP_0005550"}],"text":"There are six afucosylated antibodies in late‐stage clinical trials or approved for treatment (Table 4). Notable is obinutuzumab, an afucosyl anti‐CD20 mAb which nearly doubles progression‐free survival in chronic lymphocytic leukemia patients as compared with the fucose‐containing rituximab.68 This dramatic improvement in clinical utility reinforces the value of glycan engineering specifically and of Fc engineering generally in anticancer treatments."}

{"project":"LitCovid-sentences","denotations":[{"id":"T272","span":{"begin":0,"end":104},"obj":"Sentence"},{"id":"T273","span":{"begin":105,"end":455},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"There are six afucosylated antibodies in late‐stage clinical trials or approved for treatment (Table 4). Notable is obinutuzumab, an afucosyl anti‐CD20 mAb which nearly doubles progression‐free survival in chronic lymphocytic leukemia patients as compared with the fucose‐containing rituximab.68 This dramatic improvement in clinical utility reinforces the value of glycan engineering specifically and of Fc engineering generally in anticancer treatments."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T32","span":{"begin":206,"end":234},"obj":"Phenotype"}],"attributes":[{"id":"A32","pred":"hp_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/HP_0005550"}],"text":"There are six afucosylated antibodies in late‐stage clinical trials or approved for treatment (Table 4). Notable is obinutuzumab, an afucosyl anti‐CD20 mAb which nearly doubles progression‐free survival in chronic lymphocytic leukemia patients as compared with the fucose‐containing rituximab.68 This dramatic improvement in clinical utility reinforces the value of glycan engineering specifically and of Fc engineering generally in anticancer treatments."}